AGP Executive Report
Last update: 11 hours agoWell-being: A French study found people reported higher well-being during the COVID-19 period; everyday illness symptoms were more closely linked to how people felt than seasonal or demographic factors. Digestive health: Dr. Falk Pharma and Renexxion say the EMA and FDA have aligned on Phase 3 plans for naronapride, a potential treatment for gastroparesis, with trials expected to start in 2027. Health finances: France’s sick-leave costs are rising as the Social Security deficit widens, while thermal-spa operators are opposing plans to scrap health-insurance coverage. Medication: Ritalin prescriptions in Île-de-France have reportedly risen 122%, prompting a national health-insurance warning. Women’s health: A French study found nearly half of women report a decline in quality of life during menopause. Cancer screening: Eyonis, part of French company Median Technologies, will present AI tools for lung-nodule detection and diagnosis at an international screening conference.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
